近日，安徽皖仪科技股份有限公司（以下简称"公司"）收到国新证券股份 有限公司（以下简称"国新证券"）出具的《关于变更安徽皖仪科技股份有限公 司持续督导保荐代表人的函》，国新证券原指派肖扬女士、张展先生作为保荐代 表人负责持续督导工作。截至 2023 年 12 月 31 日，公司首次公开发行股票并上 市的法定持续督导期已届满，由于募集资金尚未使用完毕，国新证券仍需对公司 募集资金的使用情况履行持续督导义务。 证券代码：688600 证券简称：皖仪科技 公告编号：2025-054 安徽皖仪科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽皖仪科技股份有限公司董事会 2025 年 6 月 28 日 附件：乔军文先生简历 乔军文先生，男，保荐代表人、注册会计师、资产评估师，现任国新证券投 资银行部总经理。曾先后主持并参与北纬通信（002148）、明泰铝业（601677）、 天汽模（002510）、京北方（002987）、元道通信（301139）等项目的首次公开发 行工作；先后主 ...

Group 1 - Wanyi Technology and Hefei Comprehensive National Science Center Energy Research Institute signed an agreement to establish a joint laboratory for the research and development of key vacuum measurement equipment for nuclear fusion [1] - The joint laboratory will focus on developing tritium-compatible leak detection technology and vacuum measurement equipment resistant to neutron radiation and electromagnetic interference [1] - This collaboration is expected to accelerate the development of the domestic vacuum equipment industry and enhance Wanyi Technology's competitive advantage in the nuclear fusion sector [1] Group 2 - Dangsheng Technology has developed high ionic conductivity sulfide solid electrolytes with controllable micro-nano particle sizes, achieving stable production and scalability [2] - Multiple electrolyte products have received certification and integration from leading battery manufacturers and automotive companies, indicating a significant breakthrough in solid-state electrolyte technology [2] - This advancement is expected to improve battery performance and accelerate the development of the electric vehicle industry, solidifying Dangsheng Technology's leading position in the market [2] Group 3 - JinkoSolar's subsidiary achieved a record conversion efficiency of 27.02% for its 182N-type high-efficiency monocrystalline silicon cells, certified by a third-party testing center [3] - The N-type TOPCon high-efficiency photovoltaic modules also received certification, with a maximum conversion efficiency of 25.58%, setting a new record for similar products globally [3] - These breakthroughs in conversion efficiency highlight JinkoSolar's innovation capabilities and are expected to enhance the competitiveness of its products, promoting the adoption of solar energy and contributing to global energy transition [3]

Core Viewpoint - The signing of the cooperation agreement between Anhui Wanyi Technology Co., Ltd. and Hefei Comprehensive National Science Center Energy Research Institute marks the establishment of a joint laboratory aimed at advancing domestic vacuum technology and equipment industry, particularly in the field of nuclear fusion vacuum measurement [1][2]. Agreement Overview - The agreement was signed on June 22, 2025, at Wanyi Technology, and it does not require board or shareholder approval as it is not classified as a related party transaction or a major asset restructuring [2][3]. - The Energy Research Institute focuses on major scientific tasks and the construction of national large-scale scientific infrastructure, with key research areas including clean coal utilization, magnetic confinement fusion, renewable energy, and smart power grids [2][3]. Joint Laboratory Details - The joint laboratory will be established to facilitate deep integration in research and demand, technology and market, talent and industry, following principles of mutual benefit and resource sharing [3][4]. - Wanyi Technology plans to invest a total of 4 million RMB in research and development, while the Energy Research Institute will contribute 2 million RMB, matching 50% of Wanyi Technology's investment [4]. Impact on the Company - The agreement is expected to enhance the company's product advantages, brand influence, and core competitiveness, aligning with its long-term strategic development goals [4]. - The signing of the agreement will not alter the company's main business or operational scope, ensuring the company's independence and protecting shareholder interests [4].

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

安徽皖仪科技股份有限公司 关于自愿披露签署联合实验室共建协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本协议的签署仅代表双方确立了合作关系，后续具体合作细节有待进一步 商讨，实施进度和执行情况尚存在不确定性。 证券代码：688600 证券简称：皖仪科技 公告编号：2025-053 （二）关联关系说明 本协议的签署不构成关联交易，亦不构成重大资产重组，未触及公司董事会 及股东会审议标准。为便于投资者作出价值判断和投资决策，公司对本协议签署情 况进行自愿性披露。 公司将根据合作具体事项的后续进展，按照相关法律法规及《公司章程》的 规定，履行相应的审批程序和信息披露义务。 公司与能源研究院不存在关联关系。 相关风险提示：研发过程可能受限于部分技术瓶颈或因技术迭代导致无法达 到预期性研发目标的风险，敬请广大投资者注意投资风险。 近日，安徽皖仪科技股份有限公司（以下简称"公司"或"皖仪科技"）与合肥 综合性国家科学中心能源研究院（以下简称"能源研究院"）经友好协商，达成合作 意向，并签署了《联合实验室共 ...

Core Viewpoint - The company, Anhui Yi Technology (皖仪科技), has signed a joint laboratory agreement with the Energy Research Institute to establish a research lab focused on key vacuum measurement equipment for nuclear fusion, aiming to advance domestic vacuum technology and equipment industry [1] Group 1 - The joint laboratory will be named "Joint Laboratory for R&D of Key Vacuum Measurement Equipment for Nuclear Fusion" [1] - Anhui Yi Technology plans to invest 4 million yuan in research and development, while the Energy Research Institute will contribute 50% of the funding [1] - The agreement does not constitute a related party transaction or a major asset restructuring, and does not require approval from the company's board or shareholders [1]

Group 1: Company Research - Wan Yi Technology - Wan Yi Technology's main business includes industrial testing instruments, online monitoring instruments, laboratory analysis instruments, and medical instruments [1] - The company provides high-precision vacuum leak detection solutions in the nuclear fusion field, with its helium mass spectrometer reaching an internationally advanced level [1] - The development of blood dialysis equipment is progressing smoothly, with plans to submit registration applications to the National Medical Products Administration by the end of 2025 [1] - The company is enhancing profitability through improved cost and expense management [1] Group 2: Company Research - Tao Tao Vehicle - Tao Tao Vehicle's production capacity in Vietnam is expected to significantly increase, with electric golf cart production reaching new highs in June and continuing to rise in July [2] - The expansion of overseas production capacity in Southeast Asia and the U.S. is a strategic response to international trade friction, enhancing competitiveness in the U.S. market [2] - The company is well-prepared to address market shifts, benefiting from the loss of some domestic manufacturers in the U.S. market [2] Group 3: Company Overview - Xing Shi Investment - Xing Shi Investment, established in 2007, is one of China's top private equity investment management firms and a pioneer in the industry [3] - The firm has received numerous awards, including the "Morningstar China Hedge Fund Award" and the "China Private Equity Golden Bull Award," showcasing its strong investment capabilities [3] - The investment team, led by Jiang Hui, has extensive experience and has consistently delivered stable performance through various market cycles [3] - Xing Shi Investment employs a multi-layered driving factor investment approach, focusing on comprehensive research across categories, industries, and companies to identify strong investment opportunities [3]

Core Viewpoint - Company is actively engaging with various institutional investors and has a diverse range of products across multiple sectors, indicating strong market interest and potential for growth [1] Business Overview - Company operates in four main business segments: 1. Industrial Testing Instruments, including helium mass spectrometers and leak detectors, primarily used in sectors like new energy and automotive [2] 2. Online Monitoring Instruments, focusing on environmental and industrial process monitoring, applicable in industries such as petrochemicals and metallurgy [2] 3. Laboratory Analytical Instruments, offering a wide range of products for life sciences and food testing [2] 4. Medical Instruments, with products like ultrasonic knives and blood dialysis devices, entering collective procurement in Guangdong [2] Product Applications - Company's leak detection technology is crucial for vacuum systems in nuclear fusion devices, ensuring operational safety and stability [3][4][5] - Various products, including helium mass spectrometers, are applicable in semiconductor manufacturing processes [7] R&D Progress - Development of blood dialysis equipment is on track, with prototypes undergoing third-party testing and expected to submit for regulatory approval by the end of 2025 [9] Financial Performance - For Q1 2025, company reported a main revenue of 134 million yuan, a year-on-year increase of 16.87%, with a net profit loss of 5.45 million yuan, but an improvement of 83.78% [10] - The company maintains a debt ratio of 37.31% and a gross margin of 50.04% [10] Market Sentiment - In the last 90 days, four institutions rated the stock, with three buy ratings and one hold rating, indicating positive market sentiment [11] - The average target price set by institutions is 22.6 yuan [11] Earnings Forecast - Earnings projections for 2025 to 2027 show a steady increase in net profit, with estimates ranging from 53 million to 124 million yuan by 2027 [12]

Core Viewpoint - The company is conducting a differentiated profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.00 RMB per 10 shares for all shareholders, excluding shares held in the repurchase account [5][6]. Group 1: Reasons for Differentiated Profit Distribution - The company approved a share repurchase plan on November 15, 2023, using its own funds to buy back shares for employee stock ownership plans or convertible bonds [2][3]. - The total amount for the share repurchase was adjusted from a minimum of 25 million RMB to a minimum of 55 million RMB and a maximum of 105 million RMB [3][4]. - The repurchase period was extended to May 14, 2025, allowing for a longer timeframe to complete the buyback [3][4]. Group 2: Details of the Profit Distribution Plan - The company will distribute cash dividends based on a total share capital of 134,708,490 shares, deducting the repurchased shares, resulting in a base of 125,322,411 shares for the dividend calculation [6]. - The total cash dividend to be distributed amounts to approximately 12,532,241.10 RMB, including tax [6]. - The company plans to maintain the per-share distribution ratio even if the total share capital changes due to various corporate actions [6]. Group 3: Calculation Basis for the Profit Distribution - The company calculated the ex-dividend reference price using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [7]. - The actual cash dividend per share for participating shareholders is approximately 0.10 RMB, with the ex-dividend reference price calculated to be around 21.90 RMB per share [9]. - The impact of the differentiated dividend on the ex-dividend reference price is less than 1%, indicating minimal effect on share value [9]. Group 4: Conclusion - The legal opinion confirms that the differentiated profit distribution complies with relevant laws and regulations, ensuring no harm to the company or its shareholders [7][8].

Core Insights - The 2024 revenue of the domestic instrument industry shows significant differentiation, with leading companies like Antu Bio achieving counter-cyclical growth while others face challenges due to market contraction and cost pressures [2][4] Group 1: Revenue and Income Disparities - The income of executives in the instrument sector has widened significantly compared to last year, primarily driven by high dividends [4] - Antu Bio's chairman, Miao Yongjun, is the only executive with an income exceeding 100 million yuan, with 99% of his income coming from dividends [4] - The dividend payout ratio for Antu Bio is 60.28% of net profit, while Tailin Bio has an even higher ratio of 91.94%, raising concerns about sustainable development [4] Group 2: Growth Drivers and Market Challenges - The biopharmaceutical supply chain and overseas markets are identified as core growth drivers, with Antu Bio's overseas revenue increasing by 36.25% year-on-year and Wanyi Technology achieving a remarkable 447% growth [4] - Traditional sectors like environmental monitoring and industrial process analysis are under severe pressure, as evidenced by the declining income of Xuedilong's chairman, which fell from 140 million yuan in 2022 to 110 million yuan in 2023 [5] Group 3: Cost Pressures and Profitability - Cost pressures are intensifying, squeezing net profit margins across the industry, with Tailin Bio facing significant profit margin erosion due to raw material price increases and price wars [6] - Despite a 15.01% year-on-year revenue growth, Lihua Technology experienced a decline in net profit due to rising costs and increased expenses [6] - Companies like Nanwei Technology have successfully implemented quality improvement and efficiency enhancement measures, restoring growth in core business areas while controlling expenses [6] Group 4: Executive Compensation Trends - The average pre-tax salary of executives has decreased to approximately 860,000 yuan, down from 1.2 million yuan last year, reflecting cost-cutting measures amid profit pressures [9] - The compensation structure for executives in the instrument industry is evolving, emphasizing the importance of strategic transformation, industry upgrades, and cost management [9]